TY - JOUR
T1 - Modulating drug response through the gut microbiome
T2 - pathways to precision therapy
AU - Kumar, Nitish
AU - Das, Joy
AU - Vanangamudi, Murugesan
AU - Mojgani, Naheed
AU - Islam, Anas
AU - Sridhar, Sathvik Belagodu
AU - Sharma, Himanshu
AU - Kumar, Sanjesh
AU - Panigrahy, Uttam Prasad
AU - Mantry, Shubhrajit
AU - Sharma, Mayank
AU - Ramzan, Mohhammad
AU - Chaudhary, Priya
AU - Ashique, Sumel
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026.
PY - 2026/4
Y1 - 2026/4
N2 - The mutual association formed between the gut flora and the biological host is pivotal, mainly for drug action. Various examination has spotlighted the potential consequences of the gut microbiome on drug efficacy, revealing its role in controlling metabolism in the body. Furthermore, reciprocal engagement has been examined to investigate how pharmaceutical agents influence the composition of the gut microbiome. This paper emphasizes the intricate relationship between pharmacology and environmental microbiology, directing the extensive significance of pharmaceutical agents on health by controlling the gut microbial consortium. One main highlight of this review is to determine the differences observed in populace as a result of drugs, which is a crucial component in boosting personalized treatment approaches and intensifying therapeutic findings. Apart from their function in drug metabolization, the gut microbiota is disclosed as a source of metabolic products that can alter drug action. These microbially-derived metabolites could notably effect drug results and changes the body’s physical mechanisms. The investigation suggests utilizing metabolomics to disclose the complications of gut microbiota–drug interactions. Several latest analytical strategies provide an effective tool for deciphering the complicated association among microbiome-generated fragments and pharmaceutical products, providing detailed understanding into this interesting connection.
AB - The mutual association formed between the gut flora and the biological host is pivotal, mainly for drug action. Various examination has spotlighted the potential consequences of the gut microbiome on drug efficacy, revealing its role in controlling metabolism in the body. Furthermore, reciprocal engagement has been examined to investigate how pharmaceutical agents influence the composition of the gut microbiome. This paper emphasizes the intricate relationship between pharmacology and environmental microbiology, directing the extensive significance of pharmaceutical agents on health by controlling the gut microbial consortium. One main highlight of this review is to determine the differences observed in populace as a result of drugs, which is a crucial component in boosting personalized treatment approaches and intensifying therapeutic findings. Apart from their function in drug metabolization, the gut microbiota is disclosed as a source of metabolic products that can alter drug action. These microbially-derived metabolites could notably effect drug results and changes the body’s physical mechanisms. The investigation suggests utilizing metabolomics to disclose the complications of gut microbiota–drug interactions. Several latest analytical strategies provide an effective tool for deciphering the complicated association among microbiome-generated fragments and pharmaceutical products, providing detailed understanding into this interesting connection.
KW - Drug effect
KW - Drug metabolism
KW - Gut microbiome
KW - Personalized medicine
UR - https://www.scopus.com/pages/publications/105029107466
U2 - 10.1007/s00203-025-04688-3
DO - 10.1007/s00203-025-04688-3
M3 - Review article
C2 - 41627465
AN - SCOPUS:105029107466
SN - 0302-8933
VL - 208
JO - Archives of Microbiology
JF - Archives of Microbiology
IS - 4
M1 - 163
ER -